Isis Moves SMA Drug Forward As Market Interest For The Rare Disease Expands

Spinal muscular atrophy is a rare disease that affects a small patient population of children. Isis is ready to move its compound into mid-stage testing after positive Phase I results, but the biotech isn’t the only company exploring the field.

More from Clinical Trials

More from R&D